BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Lifted to “Strong-Buy” by UBS Group

UBS Group upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN) to a strong-buy rating in a report published on Wednesday morning,Zacks reports.

A number of other equities research analysts have also recently weighed in on the company. Wall Street Zen raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. HC Wainwright reissued a “neutral” rating and issued a $60.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, September 10th. William Blair upgraded BioMarin Pharmaceutical to a “hold” rating in a research report on Wednesday, September 23rd. Jefferies Financial Group raised their target price on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Finally, Weiss Ratings downgraded BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 18th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.87.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN traded down $1.37 during mid-day trading on Wednesday, hitting $54.68. The stock had a trading volume of 2,627,811 shares, compared to its average volume of 2,366,833. The stock has a market capitalization of $10.58 billion, a price-to-earnings ratio of 147.78, a P/E/G ratio of 0.39 and a beta of 0.22. The company has a 50 day simple moving average of $63.01 and a 200-day simple moving average of $58.66. BioMarin Pharmaceutical has a 52 week low of $49.26 and a 52 week high of $70.98. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The firm had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. During the same period in the previous year, the business posted $1.44 EPS. BioMarin Pharmaceutical’s revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, research analysts expect that BioMarin Pharmaceutical will post 4.10 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Large investors have recently bought and sold shares of the stock. Primecap Management Co. CA acquired a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter worth approximately $811,962,000. Dimensional Fund Advisors LP increased its stake in shares of BioMarin Pharmaceutical by 14.5% during the first quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company’s stock valued at $214,804,000 after acquiring an additional 481,176 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of BioMarin Pharmaceutical by 35.3% during the first quarter. Assenagon Asset Management S.A. now owns 1,920,658 shares of the biotechnology company’s stock valued at $108,498,000 after acquiring an additional 501,591 shares during the period. First Trust Advisors LP increased its stake in shares of BioMarin Pharmaceutical by 43.3% during the first quarter. First Trust Advisors LP now owns 1,672,491 shares of the biotechnology company’s stock valued at $94,479,000 after acquiring an additional 505,692 shares during the period. Finally, Caisse de depot et placement du Quebec bought a new stake in BioMarin Pharmaceutical during the second quarter worth approximately $70,749,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.